> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Verrica Pharma Resubmits NDA for Molluscum Drug
- URL: https://www.fdaweb.com/verrica-pharma-resubmits-nda-for-molluscum-drug/
- Published: 2021-02-17T12:00:00.000Z
- Updated: 2026-09-14T16:47:03.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5148686

Verrica Pharmaceuticals has resubmitted its NDA for VP-102 (cantharidin 0.7% topical solution), a proprietary topical therapy for treating molluscum contagiosum (molluscum). In 7/2020, FDA issued a complete response letter seeking additional chemistry, manufacturing, and controls information and human factors validation. A company [notice](https://www.globenewswire.com/news-release/2020/07/14/2061754/0/en/Verrica-Pharmaceuticals-Receives-Complete-Response-Letter-from-the-FDA-for-its-New-Drug-Application-for-VP-102-for-the-Treatment-of-Molluscum-Contagiosum.html?ref=fdaweb.com) at the time said the agency did not identify any clinical deficiencies. FDA has set a 6/23 user fee review action target date for the resubmission. The company says VP-102 is a potential first-in-class topical therapy for treating molluscum contagiosum and it also is in trials as a treatment for common warts and external genital warts.